In the 7 years since Apple released the first iPad®, how we connect, communicate, receive and share information has changed in ways we could not have imagined. Nearly every industry – from automotive to music, retail, publishing, education, construction, even farming has taken notice. They have found ways to leverage the mobility of tablet technology and take advantage of these powerful computing devices. Even healthcare – an industry notoriously slow to adopt new technology – has found in the tablet a device that many physicians like for its portability, long battery life, and ease of use.
I think it is safe to say that most of us are familiar with the risks children face when their hearing loss goes undetected. It is well documented that they may fall behind in school, have cognitive or speech delays, feel isolated, and even suffer emotionally. These are all very serious issues, and it saddens me to think about even one child who does not have access to regular hearing health care. But lately, I’ve been thinking – and reading – about risk-of-elderly-hearing-loss.
I was chatting with our founder, Dr. Matt Bromwich, over lunch yesterday. He told me about an interesting case that he had seen in the E.R. that week, and I thought it was important to share. I had never heard of Sudden Sensorineural Hearing Loss (SSNHL) before. My guess is that I’m not the only one.
If you haven’t seen the news, we announced $6M in Series A funding led by Whitecap Venture Partners. This brings the total amount invested in our company to $9.5 million to date, so we are taking a moment to celebrate.
As we wind down these last few days of 2016, I’ve been spending a lot of my time planning and preparing for the year ahead. At the top of my list has been thinking about our audiology conference agenda in 2017. Not only are we excited to share news about SHOEBOX Audiometry with our current and prospective customers, but we are always keen to hear what is happening and learn from the best and the brightest in the audiology industry.
I’m on a short plane ride home reflecting on my last few days spent with The International Union Against Tuberculosis and Lung Disease (The Union) and its affiliate Vital Strategies. Together they have been working on a Phase III Clinical Trial to test simpler and shorter treatment regimes for patients suffering from multidrug-resistant tuberculosis (MDR-TB).